SCHEMBL3431879

SCHEMBL3431879

CN1[C@@H]2CCC[C@H]1C[C@@H](NC(=O)Nc1ccc3nc(N[C@@H]4CCc5ccccc54)ccc3c1)C2

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.41
ALDH1A1 P00352 4/20 0.41
SMN1; SMN2 Q16637 1/20 0.40
NPY1R P25929 1/20 0.40
KMT2A Q03164 5/20 0.40
MEN1 O00255 2/20 0.40
MAPT P10636 1/20 0.40
POLB P06746 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
LMNA P02545 2/20 0.39
USP2 O75604 1/20 0.39
JAK2 O60674 1/20 0.39
JAK1 P23458 1/20 0.39
TYK2 P29597 1/20 0.39
JAK3 P52333 1/20 0.39
TRPV1 Q8NER1 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3431881 1.00 NPC1 (0.41) NPC1ALDH1A1SMN1; SMN2NPY1RKMT2A
SCHEMBL3411542 0.97 NPC1 (0.41) NPC1ALDH1A1NPY1RKMT2AMEN1
SCHEMBL3411547 0.97 NPC1 (0.41) NPC1ALDH1A1NPY1RKMT2AMEN1
SCHEMBL3413487 0.93 NPY1R (0.41) NPC1ALDH1A1SMN1; SMN2NPY1RKMT2A
SCHEMBL3413484 0.93 NPY1R (0.41) NPC1ALDH1A1SMN1; SMN2NPY1RKMT2A
SCHEMBL3412273 0.93 NPC1 (0.39) NPC1ALDH1A1NPY1RKMT2AMEN1
SCHEMBL4109958 0.93 NPC1 (0.39) NPC1ALDH1A1NPY1RKMT2AMEN1
SCHEMBL3413235 0.92 NPC1 (0.39) NPC1ALDH1A1SMN1; SMN2NPY1RKMT2A
SCHEMBL4114378 0.92 NPC1 (0.39) NPC1ALDH1A1SMN1; SMN2NPY1RKMT2A
SCHEMBL3412085 0.92 USP2 (0.49) NPC1ALDH1A1SMN1; SMN2NPY1RKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8183380-B2 2-aminoquinolines HOFFMANN-LA ROCHE INC. (US) 2012-05-22 US claimed
US-20090227570-A1 2-AMINOQUINOLINES HOFFMANN-LA ROCHE, INC. 2009-09-10 US claimed
US-8183380-B2 2-aminoquinolines HOFFMANN-LA ROCHE INC. (US) 2012-05-22 US disclosed
EP-2262789-A1 2-AMINOQUINOLINES F. Hoffmann-La Roche AG (CH) 2010-12-22 EP disclosed
WO-2009109477-A1 2-AMINOQUINOLINES F. HOFFMANN-LA ROCHE AG (CH) 2009-09-11 WO disclosed
US-20090227570-A1 2-AMINOQUINOLINES HOFFMANN-LA ROCHE, INC. 2009-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227570-A1 2-AMINOQUINOLINES HTR5A, HTR2C, HTR2A NPC1 2931/4885ALDH1A1 1203/4885SMN1; SMN2 3345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.